BAK1 and breast carcinoma: Remarkably, the delivery of miR‐125b ASOs using red blood cell extracellular vesicles to leukaemia MOLM13 cells and breast cancer MCF10CA1a cells results in reduced cell proliferation as the suppressed expression of miR‐125b can lead to an increased level of BAK1.131